Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for Precision Biosciences (DTIL) over the last 7 years, with Q3 2025 value amounting to $611000.0.

  • Precision Biosciences' Other Accumulated Expenses fell 5588.45% to $611000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $611000.0, marking a year-over-year decrease of 5588.45%. This contributed to the annual value of $989000.0 for FY2024, which is 5863.66% down from last year.
  • As of Q3 2025, Precision Biosciences' Other Accumulated Expenses stood at $611000.0, which was down 5588.45% from $721000.0 recorded in Q2 2025.
  • Over the past 5 years, Precision Biosciences' Other Accumulated Expenses peaked at $2.8 million during Q1 2024, and registered a low of $611000.0 during Q3 2025.
  • Its 5-year average for Other Accumulated Expenses is $1.5 million, with a median of $1.4 million in 2023.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 22093.96% in 2023, then tumbled by 6767.68% in 2025.
  • Over the past 5 years, Precision Biosciences' Other Accumulated Expenses (Quarter) stood at $977000.0 in 2021, then decreased by 23.75% to $745000.0 in 2022, then skyrocketed by 220.94% to $2.4 million in 2023, then plummeted by 58.64% to $989000.0 in 2024, then tumbled by 38.22% to $611000.0 in 2025.
  • Its last three reported values are $611000.0 in Q3 2025, $721000.0 for Q2 2025, and $896000.0 during Q1 2025.